At Prisys Biotech, we are at the forefront of pioneering drug delivery technologies, with a particular focus on advancing treatments for central nervous system (CNS) diseases. One of the most promising innovations in our portfolio is the Nasal-to-Brain (N2B) drug delivery system. This novel approach allows for non-invasive, precise drug administration directly to the brain, bypassing the blood-brain barrier (BBB) and opening new doors for neuroscience research and clinical applications.
What is N2B Technology?
The N2B (Nasal-to-Brain) delivery system is a non-invasive method that facilitates the direct transport of therapeutic agents from the nasal cavity to the brain via the olfactory bulb. This technique leverages the unique anatomical connection between the nasal passages and the brain, offering a direct route for drug delivery without the need for invasive procedures like injections or surgeries.
How Does N2B Work?
The N2B delivery system utilizes specialized devices that allow for the efficient administration of both liquid and dry powder formulations through the nose. Once delivered, the therapeutic agents travel through the olfactory nerve to reach the brain, bypassing the BBB, which is a significant obstacle in traditional CNS drug delivery methods. This approach has the potential to significantly improve the effectiveness of treatments for neurological conditions, offering a more targeted and safer alternative to current delivery methods.
Advantages of N2B Technology
Non-invasive Delivery
N2B technology provides a non-invasive alternative to traditional methods of drug administration, such as intrathecal injections or brain perfusion. This approach reduces patient discomfort, eliminates surgical risks, and improves overall treatment adherence.
Targeted Drug Delivery
The N2B system delivers drugs directly to the brain, ensuring that the therapeutic agents reach the target site with minimal systemic exposure. This targeted delivery increases the drug's efficacy and reduces the potential for off-target effects and side effects.
Bypassing the Blood-Brain Barrier
One of the major challenges in CNS drug development is the blood-brain barrier, which restricts the passage of most therapeutic agents into the brain. N2B technology bypasses this barrier, enabling researchers to deliver drugs more effectively to brain tissues, especially in the treatment of neurodegenerative diseases and brain injuries.
Versatile for Various Drug Forms
The system is designed to accommodate both liquid and dry powder formulations, providing flexibility in drug development and clinical trials. This versatility makes N2B technology suitable for a wide range of CNS treatments.
Real-time Visualization and Monitoring
The N2B delivery process is guided by advanced imaging techniques such as MRI, allowing real-time monitoring of the drug's distribution in the brain. This capability ensures the accuracy and precision of the drug delivery, optimizing therapeutic outcomes and minimizing potential complications.
N2B in Preclinical Research
Prisys Biotech's N2B technology has been extensively tested in preclinical animal models, particularly in non-human primates (NHPs). Through these studies, we have demonstrated that N2B delivers drugs to the brain with high precision and efficiency, showing strong biodistribution in target areas.
In addition to validating the system's effectiveness, our preclinical research also focuses on assessing the pharmacokinetics and pharmacodynamics of drugs delivered via the N2B method. By using imaging tools, we can track how drugs distribute in the brain, providing valuable insights for optimizing drug formulations and treatment protocols.
Application Areas in Neuroscience
N2B technology offers exciting possibilities in the treatment of a variety of neurological conditions, including:
- Alzheimer's Disease
- Parkinson's Disease
- Epilepsy
- Traumatic Brain Injury (TBI)
- Stroke
- Chronic Pain
By enabling more effective drug delivery to the brain, N2B can enhance the development of treatments for these complex disorders, improving both outcomes and the quality of life for patients.
Why Choose Prisys Biotech?
At Prisys Biotech, we are committed to advancing the field of CNS drug development with our N2B technology. Our proprietary platform is designed to support translational research, ensuring that preclinical findings seamlessly transition to clinical applications. With our facilities, including our AAALAC-accredited NHP vivarium, and advanced imaging systems, we are equipped to deliver high-quality, reproducible research results.
Our N2B drug delivery system is part of a broader range of capabilities designed to support researchers and pharmaceutical companies in the development of novel CNS therapies. With our deep expertise and cutting-edge technologies, we are a trusted partner in advancing neuroscience research and drug development.
Prisys Biotech's Nasal-to-Brain (N2B) drug delivery technology represents a significant leap forward in the treatment of CNS disorders. By providing a non-invasive, targeted, and efficient method for delivering drugs directly to the brain, N2B is poised to revolutionize the way we approach neurological disease treatment. Whether you are involved in early-stage drug discovery or clinical development, N2B technology offers a promising solution for accelerating the progress of CNS therapies.
